206 related articles for article (PubMed ID: 35568624)
21. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Zafar A; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Martin TG; Shah N; Banerjee R
Transplant Cell Ther; 2023 Aug; 29(8):504.e1-504.e7. PubMed ID: 37244643
[TBL] [Abstract][Full Text] [Related]
22. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
23. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
24. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.
Zhou Y; Mu W; Wang C; Zhuo Z; Xin Y; Li H; Wang C
BMC Cancer; 2023 Oct; 23(1):1019. PubMed ID: 37872514
[TBL] [Abstract][Full Text] [Related]
25. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
26. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M; Nguyen A; Hussain A; Ammad-Ud-Din M; Faisal MS; Tariq E; Ali F; Butt A; Anwar I; Chaudhary SG; Lutfi F; Ahmed N; Singh AK; Hematti P; McGuirk JP; Mushtaq MU
Front Immunol; 2023; 14():1152457. PubMed ID: 37168849
[TBL] [Abstract][Full Text] [Related]
27. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
29. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
31. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
32. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC; Gunther JR; Dabaja BS; Strati P; Fang P; Hawkins MC; Adkins S; Westin J; Ahmed S; Fayad L; Lee HJ; Nair R; Steiner RE; Iyer SP; Rodriguez MA; Wang M; Flowers C; Neelapu SS; Nastoupil LJ
Blood Adv; 2020 Jul; 4(13):2871-2883. PubMed ID: 32589728
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Grover P; Veilleux O; Tian L; Sun R; Previtera M; Curran E; Muffly L
Blood Adv; 2022 Mar; 6(5):1608-1618. PubMed ID: 34610109
[TBL] [Abstract][Full Text] [Related]
34. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience.
Trando A; Ter-Zakarian A; Yeung P; Goodman AM; Hamdan A; Hurley M; Jeong AR; Tzachanis D
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760639
[TBL] [Abstract][Full Text] [Related]
38. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
Guo M; Wang X; Xiao S; Liu A; Xu T; Huan C; Wu H; Hu Y; Zhou S; Zhu H; Pan D
Clin Exp Med; 2023 Oct; 23(6):2041-2050. PubMed ID: 36930381
[TBL] [Abstract][Full Text] [Related]
39. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
40. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
